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Regulatory T (Treg) cells play a pivotal role in sup-
pressing self-harmful T cell responses, but how
Treg cells mediate suppression to maintain immune
homeostasis and limit responses during inflamma-
tion is unclear. Here we show that effector Treg cells
express high amounts of the integrin avb8, which en-
ables them to activate latent transforming growth
factor-b (TGF-b). Treg-cell-specific deletion of integ-
rin avb8 did not result in a spontaneous inflamma-
tory phenotype, suggesting that this pathway is not
important in Treg-cell-mediated maintenance of
immune homeostasis. However, Treg cells lacking
expression of integrin avb8 were unable to suppress
pathogenic T cell responses during active inflamma-
tion. Thus, our results identify a mechanism by which
Treg cells suppress exuberant immune responses,
highlighting a key role for effector Treg-cell-mediated
activation of latent TGF-b in suppression of self-
harmful T cell responses during active inflammation.
INTRODUCTION
Regulatory T (Treg) cells, a subset of CD4+ T cells expressing the
transcription factor Foxp3, are crucial in regulating self-harmful
T cell responses. Treg cells can develop in the thymus (so-called
thymic Treg cells [tTreg cells]) or be induced in the periphery via
upregulation of Foxp3 (pTreg cells) (Rudensky, 2011). Mutations
in Foxp3 cause severe T-cell-mediatedmulti-organ inflammation
in both mice and humans, highlighting a critical role for Treg cells
in maintaining T cell homeostasis. Additionally, the transfer of
Treg cells into mouse models of inflammatory disease activelysuppresses harmful T cells to prevent inflammation (Maloy and
Powrie, 2011). There are current clinical trials using Treg cells
that attempt to dampen T cell responses in several human in-
flammatory disorders (Tang and Bluestone, 2013). Thus, it is
paramount that the mechanisms by which Treg cells control im-
munity be determined, to identify pathways that can be targeted
to promote Treg cell function.
A crucial molecule that controls many aspects of Treg cell
biology is the cytokine transforming growth factor-b (TGF-b).
TGF-b plays a fundamental role in the development of Treg cells,
both in the induction pTreg cells (Chen et al., 2003) and in the
development of tTreg cells (Konkel et al., 2014; Liu et al.,
2008). In addition to roles in Treg cell development, TGF-b plays
a fundamental role in the functional ability of Treg cells to sup-
press T cell responses. Although initial in vitro assays of Treg-
cell-mediated suppression both supported and contradicted a
functional role for TGF-b (Dieckmann et al., 2001; Jonuleit
et al., 2001; Marie et al., 2005; Nakamura et al., 2001; Oida
et al., 2006; Takahashi et al., 1998; Thornton and Shevach,
1998), there is now clear evidence that TGF-b plays a key role
in mediating Treg cell suppressive function in vivo. Thus,
T cells with a reduced capacity to respond to TGF-b cannot be
suppressed by Treg cells in mouse models of colitis (Fahle´n
et al., 2005; Liu et al., 2003) and experimental autoimmune
encephalomyelitis (Zhang et al., 2006), and production of TGF-
b1 by Treg cells is required for their suppression of colitic
T cells in vivo (Nakamura et al., 2004; Pesu et al., 2008). Although
some studies have suggested that TGF-b1-deficient Treg cells
are still capable of suppressing T-cell-mediated colitis (Fahle´n
et al., 2005; Kullberg et al., 2005), this suppression is completely
abolished by an anti-TGF-b-blocking antibody (Fahle´n et al.,
2005), again highlighting the crucial role of TGF-b in Treg-cell-
mediated suppression in vivo. However, although TGF-b plays
a crucial, non-redundant role in suppression of T cells by Treg
cells in vivo, how TGF-b is regulated to mediate Treg cell sup-
pressive function is poorly understood.Immunity 42, 903–915, May 19, 2015 ª2015 The Authors 903
TGF-b is always produced as an inactive precursor, which
must be activated in order to bind its receptor and produce bio-
logical function (Worthington et al., 2011a). The tgfb gene en-
codes latency-associated peptide (LAP) upstream of the active
TGF-b moiety, which is cleaved from the active cytokine but re-
mains non-covalently attached in a conformation that prevents
TGF-b from engaging its receptor. Known activators of TGF-b
include a variety of proteases and cell surface molecules
that somehow alter the latent complex so that active TGF-b
can engage its receptor (Worthington et al., 2011a). Activation
of the latent complex is therefore essential for regulation of
TGF-b function, yet how TGF-b activation is regulated to control
Treg cell suppressive function is completely unknown. Addition-
ally, whether TGF-b plays an important role in Treg-cell-medi-
ated suppression in all situations or whether this pathway is
important in only certain immunological settings is a crucial but
unanswered question.
Here we show that Foxp3+ Treg cells are specialized activa-
tors of TGF-b via expression of the integrin avb8 and that expres-
sion of the integrin is upregulated on activated/effector (e)Treg
cells, indicating a potential role in Treg-cell-mediatedmodulation
of active inflammation. Indeed, although lack of expression of
integrin avb8 on Treg cells does not result in a break in Treg-
cell-mediated tolerance at rest, Treg cells lacking expression
of the integrin are completely unable to suppress T-cell-medi-
ated inflammation in vivo. These results therefore identify a
mechanism by which activated/eTreg cells specifically control
inflammatory T cells, highlighting a key role for Treg-cell-medi-
ated activation of latent TGF-b in suppression of self-harmful
T cell responses.
RESULTS
Treg Cell Expression of the TGF-b-Activating Integrin
avb8 Is Vital for Suppressing T Cell Expansion
Despite the importance of TGF-b in mediating suppression of
T cells by Foxp3+ Treg cells in vivo, the mechanisms by which
this suppression occurs are unknown. Because TGF-b is
expressed as a latent complex, we hypothesized that Treg
cells could be specialized to activate TGF-b in order to increase
local concentrations of the cytokine to mediate suppression.
To test this hypothesis, we co-cultured naive CD4+ T cells
(CD45RBhiFoxp3), effector/memory CD4+ T cells (CD45RBlo
Foxp3), and Treg cells (CD45RBloFoxp3+) with cells expressing
a luciferase reporter for active TGF-b (Abe et al., 1994). Interest-
ingly, Foxp3+ Treg cells showed an enhanced ability to activate
latent TGF-b compared with both naive and effector/memory
T cells (Figure 1A). To determine mechanisms by which Foxp3+
Treg cells are specialized to activate TGF-b, we examined Treg
cells for molecules that could potentially activate the latent cyto-
kine. We focused on the potential role of integrin avb8, which we
have previously shown to be expressed by tolerogenic dendritic
cells, enabling them to activate TGF-b, a pathway that is crucial
in controlling immune homeostasis and responses to infec-
tion (Travis et al., 2007; Worthington et al., 2011b, 2013). We
analyzed expression of the integrin b8 subunit (which pairs
only with integrin av) at the RNA level, because there are no cur-
rent antibodies available that recognize murine integrin b8. We
found that Foxp3+ Treg cells expressed 100-fold higher levels904 Immunity 42, 903–915, May 19, 2015 ª2015 The Authorsof integrin b8 mRNA than naive and effector memory CD4+
T cells (Figure 1B). Expression of integrin av (which pairs with
the additional subunits b1, b3, b5, and b6) was similar in all
T cell subsets (Figure S1A). Using Treg cells isolated from mice
expressing a conditional allele of integrin b8 (Itgb8) combined
with Cd4-Cre (herein called Itgb8 KO Treg cells) (Travis et al.,
2007), we found that such cells no longer displayed the height-
ened activation of latent TGF-b compared to control Treg cells
(Figure 1C). These results suggest that Treg cells activate
enhanced levels of TGF-b versus other T cell subsets via expres-
sion of integrin avb8.
We next tested the suppressive capacity of Itgb8KOTreg cells
via a model of CD4+ T cell expansion in vivo, where naive T cells
expand within a few days of transfer into a lymphopenic Rag2/
mouse (Workman et al., 2011). Both control and Treg cells lack-
ing expression of integrin b8 were isolated to similar purities
(>94% Foxp3+) before transfer (Figures S1B and S1C). We found
that Itgb8 KO Treg cells showed a complete failure to suppress
T cell expansion compared to the reduction seen with control
Treg cells (Figure 1D). This lack of suppression was not due to
any alterations in Treg cell establishment or loss of Foxp3
expression, as shown by the fact that equivalent percentages
and Foxp3 expression was found in both transferred control
and Itgb8 KO Treg cells (Figure 1E). In the presence of control
Treg cells, we observed a specific increase in phosphorylation
of Smad 2/3 (pSmad2/3) in CD4+ T cells (Figure 1F), which
is the initial signaling event triggered by engagement of TGF-b
with its receptor (Worthington et al., 2011a). CD4+ T cell
pSmad2/3 levels were lower in the presence of Itgb8 KO Treg
cells, indicating that T cells were not seeing as much active
TGF-b in the presence of integrin b8-deficient Treg cells (Fig-
ure 1F). There was no difference in the amount of pSmad2/3
between the control and Itgb8 KO Treg cells, indicating that
the difference in TGF-b signaling was specific to transferred
T cells and not Treg cells at this time point (Figure 1F). Taken
together, these data indicate that Foxp3+ Treg cells preferentially
activate TGF-b via expression of integrin avb8 and that this
mechanism is essential for the ability of Treg cells to suppress
CD4+ T cell expansion in vivo.
Foxp3+ Treg Cell Expression of Integrin avb8 Is Not
Required to Maintain T Cell Homeostasis
We have previously demonstrated that mice lacking integrin
avb8 on all T cells demonstrate no immune pathology at rest
(Travis et al., 2007). To directly test the role of this pathway in
Treg-cell-mediated control of T cell homeostasis, we crossed
mice expressing a conditional allele of integrin b8 with mice ex-
pressing foxp3YFP-Cre (Itgb8 flox/flox [fl/fl] 3 foxp3YFP-Cre mice,
herein called Itgb8fl/flfoxp3YFP-Cre mice) to specifically delete
the integrin on Foxp3+ Treg cells (Rubtsov et al., 2008). Despite
Treg-cell-expressed integrin avb8 being essential for suppres-
sion of T cell expansion (Figure 1D), we found that Itgb8fl/fl
foxp3YFP-Cre mice developed no spontaneous inflammatory
phenotype. Thus, such mice display similar T cell development
(Figure 2A) and T cell numbers in spleen and intestinal tissue (Fig-
ure 2B) when compared to control mice. There were also similar
Treg cell quantities in these compartments, although a slight
increase in the splenic Treg cell population was observed (Fig-
ure 2C), consistent with a previous report that mice lacking
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Figure 1. Foxp3+ Treg Cells Express the
TGF-b-Activating Integrin b8, which Is
Essential for Suppression of T Cell Expan-
sion In Vivo
(A) TGF-b activation by naive (CD45RBhiFoxp3),
effector/memory (CD45RBloFoxp3), and Treg
(CD45RBloFoxp3+) CD4+ T cell subsets isolated
from the spleen of foxp3GFP mice, detected by co-
culture with an active TGF-b reporter cell line. Data
(n = 4) are from two independent experiments.
(B) RNA from naive, effector/memory, and Treg
cell CD4+ T cell subsets was isolated from the
spleen of foxp3GFP mice and analyzed for integrin
b8 expression by qPCR, with levels normalized to
the housekeeping gene Hprt and presented rela-
tive to naive T cells. Data (n = 2–5) are from five
independent experiments.
(C) TGF-b activation by control (Itgb8fl/flCre) or
Itgb8 KO (Itgb8fl/flCd4-Cre+) splenic Treg cells
(CD4+CD45RBloCD25hi), detected by co-culture
with an active TGF-b reporter cell line as in (A). Data
(n = 7) are from five independent experiments.
(D) Naive (CD4+CD45RBhiCD25) T cells from
CD45.1+ congenic mice were transferred into
Rag2/mice at a ratio of 4:1 with control or Itgb8
KO Treg cells (CD4+CD45RBloCD25hi). Numbers
of transferred CD45.1+ naive T cells in the spleen
of recipient mice were determined 7 days later.
Data (n = 8) are from six independent experiments.
(E) Representative flow cytometry plots from
(D) and mean percentage Foxp3 expression of
transferred Treg cell populations.
(F) Analysis of pSmad2/3 expression by flow
cytometry in transferred CD4+ T cells (CD45.1+
CD3+CD4+) and transferred control/Itgb8 KO Treg
cells (CD45.1CD3+CD4+Foxp3+) from spleen
7 days post transfer. Data (n = 5) are from three
independent experiments.
Error bars represent SEM. See also Figure S1.TGF-b signaling specifically on Foxp3+ Treg cells show slightly
elevated Treg cell numbers (Gutcher et al., 2011). Similar T cell
activation and cytokine profiles were observed in intestinal tis-
sue, with a slightly increased T cell activation and CD4+ IFN-g
production observed in the splenic T cell population (Figures
2D and 2E). However, this slight increase in splenic T cell activa-
tion did not appear biologically significant; mice appeared
healthy up until at least 12 months of age and showed no signs
of colitis (Figure 2F) or immune pathology in organs examined
(Figure 2G). These results indicate that TGF-b activation by
Treg-cell-expressed integrin avb8 is not required for Treg-cell-
mediated control of T cell tolerance at rest.Immunity 42, 903–9Integrin avb8 Is Preferentially
Expressed on Activated Foxp3+
Treg Cells
Given that integrin avb8 expression by
Tregcells appeared essential for suppres-
sion of T cell expansion but redundant for
Treg-cell-mediated maintenance of T cell
homeostasis, we hypothesized that acti-
vation of latent TGF-b by Treg-cell-ex-
pressed integrin avb8 might play a roleduring inflammatory responses when both CD4+ T cells and
Treg cells are activated. We first examined expression of integrin
b8 on resting versus activated Treg cell subsets. We found that,
whereas activation of naive CD4+ T cells did not alter expression
of the integrin, activation of Treg cells with anti-CD3 and anti-
CD28 antibodies increased expression of integrin b8 (Figure 3A),
with integrin av expression remaining unaltered (Figure S2A).
Furthermore, activated Treg cells had increased capacity to acti-
vate TGF-b, which was completely dependent on the expression
of integrin avb8 by activated Treg cells (Figure 3B). We next
determined whether integrin avb8 was preferentially expressed
on activated Treg cell subsets in vivo. Indeed, we found highly15, May 19, 2015 ª2015 The Authors 905
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Figure 2. Mice Lacking Foxp3+ Treg Cell
Expression of Integrin b8 Display Normal T
Cell Homeostasis
Control mice (Itgb8fl/fl) and mice lacking expres-
sion of integrin b8 on Treg cells (Itgb8fl/fl
foxp3YFP-Cre), aged 6–12 months old, were exam-
ined for potential disruption of T cell homeostasis
and inflammation.
(A) Representative flow cytometry plots of
thymic T cell populations analyzed via CD4/CD8
expression.
(B) Spleen, mesenteric LN (mLN), and large intes-
tinal lamina propria (LILP) were examined for T cell
cellularity.
(C) Spleen, mLN, LILP, and thymuswere examined
for percent Foxp3+ Treg cells.
(D and E) Percent CD4+ and CD8+ effector/mem-
ory T cell subsets (CD44hiCD62lo) (D) and percent
intracellular IFN-g and IL-17 expression by CD4+
T cells (E) was examined by flow cytometry.
(F) Colitic score and representative images of
Itgb8fl/fl and Itgb8fl/flfoxp3YFP-Cre mice colon.
(G) Representative histological sections of organs
from Itgb8fl/fl and Itgb8fl/flfoxp3YFP-Cre mice.
Data represent n = 4–5.
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Figure 3. The TGF-b-Activating Integrin avb8 Is Preferentially
Expressed on Effector Treg Cells
(A) RNA from non-activated or anti-CD3 and anti-CD28 antibody-activated
naive (CD45RBhiFoxp3) or Treg (CD45RBloFoxp3+) CD4+ T cell subsets iso-
lated from the spleen of foxp3GFP mice and analyzed for integrin b8 expression
by qPCR. Integrin b8 levels were normalized to the housekeeping gene Hprt
and presented relative to levels in naive T cells. Data (n = 4–8) are from three
independent experiments.
(B) TGF-b activation by unstimulated or anti-CD3 and anti-28 antibody-acti-
vated splenic control (Itgb8fl/flCre) or Itgb8 KO (Itgb8fl/flCd4-Cre+) Treg cells
(CD4+CD45RBloCD25hi), detected by co-culture with an active TGF-b reporter
cell line. Data (n = 4–8) are from four independent experiments.
(C) Integrin b8 levels were assessed by qPCR via RNA isolated fromKLRG1+ or
KLRG1 Treg cells (CD45RBloFoxp3+, isolated from foxp3GFP mice) and
values normalized to Hprt and displayed relative to naive CD4+ T cells in (A).
Data (n = 4–8) are from three independent experiments.
(D) TGF-b activation levels from KLRG1+ or KLRG1 Treg cell subsets
(CD4+CD45RBloCD25hiKLRG1+/ cells) either control or Itgb8 KO, assessed
by co-culture with a TGF-b reporter cell line as described in (B). Data (n = 4–5)
are from three independent experiments.
Error bars represent SEM. See also Figure S2.elevated expression of integrin b8 mRNA by KLRG1+ Treg cells
(Figure 3C), which are a subset of Treg cells proposed to repre-
sent a terminally differentiated activated/eTreg cell state (Feuerer
et al., 2010). The integrin av was also highly expressed on this
KLRG1+ eTreg cell population (Figure S2B). Similar to in vitro
activated Treg cells, KLRG1+ Treg cells showed significantly
elevated ability to activate latent TGF-b versus KLRG1 Treg
cells, which was completely dependent on the expression of in-
tegrin avb8 (Figure 3D). Taken together, these data demonstrate
that integrin avb8 is expressed primarily on activated Treg cells,
especially on terminally differentiated eTreg cells.
Integrin avb8 Expression Is Essential for Treg Cell
Suppressive Function during Inflammation
Given the elevated expression of integrin avb8 on eTreg versus
non-eTreg cells, we hypothesized that integrin avb8 expressionmight play an essential role in preventing immunopathology dur-
ing ongoing inflammation. To address this possibility, we utilized
the T cell transfer model of colitis, which acts as an in vivo
model for Treg cell suppression of inflammatory T cells (Powrie
et al., 1994). In this model, Rag2/ mice receive naive (CD4+
CD45RBhiCD25) T cells, resulting in a wasting disease after
6–8 weeks, which can be reversed by transfer of Treg cells (Ma-
loy et al., 2005).
Given that KLRG1+ Treg cells express significantly elevated
levels of functional integrin avb8 (Figures 3C and 3D), we initially
tested whether KLRG1+ Treg cell numbers are altered during
inflammation. To this end, we examined Treg cell populations
during homeostasis compared to Treg cells at 6 weeks after
transfer into colitic mice. We found that, compared to Treg cells
at rest, the percentage of KLRG1+ eTreg cells in the transferred
population was significantly increased in splenic, mLN, and in-
testinal tissues (Figure 4A) and that these KLRG1+ Treg cells ex-
pressed high levels of integrin b8 mRNA (Figure 4B). Thus, these
data indicate that exposure to an inflammatory environment
causes an expansion of the KLRG1+ eTreg cell subset express-
ing high amounts of integrin b8.
To directly test the functional role for integrin avb8 expression
by Treg cells in their ability to suppress inflammatory T cell
responses, we tested the suppressive ability of Treg cells lacking
expression of integrin b8 in the transfer colitis model. When Treg
cells were transferred at a time when inflammation was not yet
present (i.e., at the same time as naive T cells), both control
and Itgb8 KO Treg cells completely suppressed weight loss
and the development of colitis (Figures S3A–S3D), in agreement
with recent findings (Edwards et al., 2014) and the findings that
integrin b8 expression on Treg cells does not play a function
in preventing inflammation during homeostasis (Figure 2).
However, when Treg cells were transferred 2 weeks after naive
CD4+ T cell transfer into an inflammatory environment, Itgb8
KO Treg cells completely failed to rescue disease, with weight
loss and histological scores being indistinguishable from mice
not receiving Treg cells (Figures 4C and 4D). This lack of sup-
pression was in contrast to control Treg cells, which completely
suppressed weight loss and inflammation (Figures 4C, 4D, S3E,
and S3F).
Previous work has demonstrated that Treg cells suppress
both the innate and adaptive arms of the immune response dur-
ing T-cell-induced colitis (Maloy et al., 2003). However, when
transferred 2 weeks after initial naive T cells, Itgb8 KO Treg cells
demonstrated no suppressive ability against either the innate or
adaptive immune response, with mice receiving Itgb8 KO Treg
cells showing equivalent numbers of tissue inflammatory mono-
cytes/macrophages (CD11b+Gr1int), neutrophils (CD11b+Gr1hi)
(Figure 4E; Griseri et al., 2012), and both IFN-g+ and IL-17+
CD4+ T cells (Figure 4F), as seen in the absence of Treg cells.
Indeed, Itgb8 KO Treg cells failed to reduce the total levels of
the inflammatory cytokines IFN-g and IL-17 produced by cells
of the large intestinal lamina propria (Figure 4G).
Next, we determined the function of integrin avb8 expression
by Treg cells in a non-lymphopenic model of colonic inflamma-
tion, via feeding of control (Itgb8WT/flfoxp3YFP-Cre) and Itgb8fl/fl
foxp3YFP-Cre mice with a low dose of dextran sodium sulfate
(DSS). Mice lacking Treg cell integrin b8 expression showed
exacerbated colitis compared to control mice expressingImmunity 42, 903–915, May 19, 2015 ª2015 The Authors 907
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Figure 4. Treg Cells Convert to KLRG1+
Effector Treg Cells during Transfer Colitis
and Expression of Integrin b8 by Treg Cells
Is Essential to Rescue Ongoing Inflammation
Rag2/ mice received 0.5 3 106 CD45RBhi T cells
alone or followed 2 weeks later by 0.25 3 106 con-
trol (Itgb8fl/flCre) or Itgb8 KO (Itgb8fl/flCd4-Cre+)
Treg cells (CD4+CD45RBloCD25hi).
(A) Expression of KLRG1 on transferred Foxp3+
Treg cells (from foxp3GFP mice) 6 weeks after
transfer versus non-transferred Treg cells.
(B) Integrin b8 levels were assessed on KLRG1+
or KLRG1 Treg cells ex vivo by qPCR using
RNA isolated from transferred Treg cells (CD4+
CD45RBhiFoxp3GFP+) 6 weeks after transfer and
values normalized to Hprt and displayed relative to
naive CD4+ T cells.
(C and D) Percent of initial mouse weight from time
of Treg cell transfer (C) and representative H&E
staining and colitic scores of colon samples (D).
(E) Neutrophil (Gr1hiCD11b+) and monocyte/
macrophage (Gr1intCD11b+) populations from the
LILP. Total cell number and representative flow
cytometry plots are displayed.
(F) Intracellular IFN-g and IL-17 expression in CD4+
T cells from LILP. Total cell number and represen-
tative flow cytometry plots of data are displayed.
(G) IFN-g and IL-17 cytokine levels from anti-CD3
and anti-CD28 antibody-stimulated total LILP cells,
determined via ELISA.
Data in (A) and (B) (n = 2–4) are from two indepen-
dent experiments and in (C)–(G) (n = 5–13) are from
four independent experiments. Error bars represent
SEM. See also Figure S3.
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Figure 5. Absence of Integrin b8 on Treg
Cells Exacerbates Intestinal and Peripheral
Inflammatory T Cell Responses in Lympho-
cyte-Replete Mice
(A–C) Control (Itgb8WT/flfoxp3YFP-Cre) and Itgb8
Treg cell KO (Itgb8fl/flfoxp3YFP-Cre) mice received
1% DSS in drinking water for 9 days.
(A) Percentage of initial weight from time of treat-
ment. Error bars represent SEM.
(B and C) Percentage CD4+ T cell populations from
the LILP (B) and H&E staining of colon samples (C)
at day 9 post-treatment. Data (n = 5) are repre-
sentative of two independent experiments.
(D–F)Controlmice (Itgb8fl/flor Itgb8WT/flfoxp3YFP-Cre)
and mice lacking Itgb8 expression in Treg cells
(Itgb8fl/flfoxp3YFP-Cre) were immunized with oval-
bumin/CFA followed by subcutaneous challenge
with PBS in the left ear pinna and ovalbumin in the
right.
(D and E) Mean ear thickness (D) and H&E staining
of ears (E) 48 hr after challenge.
(F) Intracellular IFN-g expression in CD4+ and
CD8+ T cells from ear draining lymph node. Total
cell number and representative flow cytometry
plots of data are displayed. Data (n = 6–7) are from
two independent experiments.Foxp3-YFP-Cre, showing enhanced weight loss (Figure 5A),
increased CD4+ T cell numbers (Figure 5B), and enhanced pa-
thology (Figure 5C), suggesting an important functional role for
integrin avb8 expression on Treg cells in controlling intestinal
inflammation. Finally, to test whether the suppressive function
of integrin avb8 expression on Treg cells was specific for sup-
pression of inflammation in the intestine, we induced delayed-
type hypersensitivity (DTH) in the ears of mice (Lahl et al.,Immunity 42, 903–92007). Itgb8fl/flfoxp3YFP-Cre mice showed
exacerbated inflammation compared to
controls (both Itgb8fl/fl [Cre-negative]
and Itgb8WT/flfoxp3YFP-Cre control mice),
with enhanced ear thickness (Figure 5D)
and inflammation (Figure 5E) and
enhanced numbers of CD4+ and CD8+
T cells producing IFN-g (Figure 5F).
Thus, taken together, these results show
that, despite the ability of Treg cells lack-
ing expression of integrin avb8 to main-
tain T cell homeostasis and prevent initial
development of inflammation in vivo,
expression of this integrin is required for
the capacity of Treg cells to suppress
effector T cells during inflammation.
Lack of Integrin avb8 Expression
Does Not Alter the Homing,
Maintenance, or Stability of Treg
Cells
The defect in suppression of active
inflammation by Itgb8 KO Treg cells
raised the possibility that lack of integrin
avb8 expression altered either Treg cellsurvival, stability, or homing to tissues during homeostasis
and/or inflammation. To address this possibility, we first
analyzed female mice that were heterozygous for foxp3YFP-Cre.
Because of the location of foxp3 on the X chromosome and its
random inactivation in females, such mice that are homozygous
for the integrin b8 floxed allele are a natural chimera for Itgb8-ex-
pressing and KO Treg cells. We found equivalent ratios of Cre
(Foxp3+YFP) and Cre+ (Foxp3+YFP+) Treg cells in all locations15, May 19, 2015 ª2015 The Authors 909
tested (spleen, mLN, LILP) between mice that were flox/flox for
the Itgb8 conditional allele (WT/KO chimera) or WT for the
Itgb8 allele (WT/WT chimera) (Figure 6A). Additionally, Itgb8-ex-
pressing and Itgb8 KO Treg cells expressed equivalent amounts
of a range of Treg-cell-associated markers (Table S1). Together,
these data indicate that lack of integrin b8 on Treg cells does not
alter the development, maintenance, homing, or stability of Treg
cells during homeostasis.
Next, to test whether there was any defect when transferred to
an inflammatory environment, we performed transfer colitis ex-
periments, analyzing control or Itgb8 KO Treg cells transferred
to colitic Rag2/ mice that had received naive CD4+ T cells
2 weeks earlier. At 6 weeks after transfer, equivalent percent-
ages of both control and Itgb8 KO Treg cells were observed in
the intestine of recipient mice (Figures 6B and 6C), strongly sug-
gesting that integrin avb8 expression by Treg cells is not required
for either their migration or maintenance in the intestine during
inflammation. We also observed equivalent levels of Foxp3+
Treg cells arising from the transferred naive T cell population
(i.e., induction of pTreg cells) (Figures 6B and 6C), which has pre-
viously been shown to rely on TGF-b (Chen et al., 2003), indi-
cating that Treg cell expression of integrin avb8 is not involved
in the generation of pTreg cells during inflammation. Further-
more, equivalent percentage of Foxp3 expression in control
and Itgb8 KO Treg cells was observed after transfer (Figure 6D),
and these cells expressed equivalent quantities of Foxp3 (Fig-
ure 6E), indicating that TGF-b activation mediated by integrin
avb8 on Treg cells is not required for the stability of Foxp3
expression. Indeed, Treg cells lacking expression of integrin
avb8 did not upregulate expression of the pro-inflammatory
cytokines IFN-g and IL-17 upon transfer (Figures 6F and 6G)
and did not cause any pathology when transferred alone to
mice (Figures S4A–S4E). Also, despite their failure to rescue dis-
ease, Itgb8 KO Treg cells had a similar capacity to become
KLRG1+ eTreg cells, with equivalent expression of both KLRG1
and the additional Treg cell activation marker CD103 compared
to control Treg cells (Figures S4F–S4G).
Treg cells lacking expression of integrin b8 could not rescue
colitis, which meant that control and Itgb8 KO Treg cells were
subjected to different intestinal environments. To determine
whether anydefects in Treg cellmaintenance, stability, or homing
were apparent in cells present in the same inflammatory context,
we co-transferred a 50:50 mix of b8-expressing (Itgb8WT/WT
foxp3YFP-Cre or Itgb8WT/WTfoxp3YFP-Cre+) and integrin b8-defi-
cient (Itgb8fl/ffoxp3YFP-Cre+) Treg cells into colitic mice. 2 weeks
later (a time when mice still had intestinal inflammation), the ratio
of Itgb8-expressing and Itgb8-deficient Treg cells was identical
to that observed when a 50:50 mix of Itgb8WT/WTfoxp3YFP-Cre
and Itgb8WT/WTfoxp3YFP-Cre+ Treg cells were transferred (Fig-
ure S4H). These data strongly indicate that lack of integrin b8
does not affect Treg cell maintenance, stability, or homing in
an inflammatory context. Additionally, expression of a range of
Treg-cell-associated functional markers showed equivalent
expression in both Itgb8-expressing and Itgb8-deficient Treg
cells isolated after co-transfer into colitic mice (Table S2). Finally,
when natural chimera mice (female Itgb8fl/fl mice heterozygous
for foxp3YFP-Cre) were subjected to either DSS colitis or DTH
models, there were no differences in Itgb8-expressing (YFP)
and Itgb8-deficient (YFP+) Treg cell ratios compared to equiva-910 Immunity 42, 903–915, May 19, 2015 ª2015 The Authorslent populations in chimeraswhere all Treg cells expressed integ-
rin b8 (Figures S4I and S4J). Taken together, these data further
suggest that lack of functional suppression by Treg cells lacking
expression of integrin b8 is not due to defective homing, migra-
tion, stability, or activation of these cells.
Lack of Treg-Cell-Expressed Integrin avb8 Dampens
TGF-b Signaling in Colitic T Cells and Treg Cells
Because data suggest that TGF-b signalling is required in T cells
to permit Treg-cell-mediated suppression in vivo and because
activated/eTreg cells activate high levels of TGF-b via integrin
avb8, we next tested whether colitic T cells showed enhanced
TGF-b signalling in the presence of Treg cells in an integrin
avb8-dependent manner. We found that the transfer of control
Treg cells to mice resulted in an increase in pSmad2/3 in trans-
ferred CD4+ colitic T cells but that this increase in the TGF-b
signaling pathway was almost completely absent in the pres-
ence of Itgb8 KO Treg cells (Figures 6H and 6I). Additionally,
there was a difference between the transferred control and
Itgb8 KO Treg cells themselves, with reduced levels of
pSmad2/3 observed in the Itgb8 KO Treg cell populations at
this time point (Figures 6H and 6I). When T cells and Treg cells
were co-transferred together into mice (a situation where Itgb8
KO Treg cells completely prevented colitis [Figures S3A–S3D]),
pSmad2/3 in transferred T cells was equivalent in the presence
of both control or Itgb8 KO Treg cells 6 weeks after transfer (Fig-
ure S4K), indicating that during Treg-cell-mediated prevention of
colitis, TGF-b signaling in T cells does not require integrin b8
expression on Treg cells. Thus, taken together, our results sug-
gest that expression of integrin avb8 is required for Treg-cell-
mediated suppression of inflammation via activation of TGF-b,
which triggers TGF-b signaling in both colitic CD4+ T cells and
Foxp3+ Treg cells.
Integrin avb8 Is Preferentially Expressed on Human
eTreg Cell Populations
Finally, we addressed whether the expression of integrin avb8
seen on mouse Treg cells was mirrored by human Treg cells.
We found that, similar to results in mice, Foxp3+ Treg cells
from human blood preferentially expressed integrin b8 mRNA
compared to naive or effector/memory CD4+ T cells (Figure 7A).
Total human Foxp3+ Treg cells also expressed enhanced
amounts of the integrin av subunit (Figure S5A).
We next sought to determine whether expression of integrin
avb8was enriched on eTreg cells in humans, similar to our obser-
vations in mice (Figure 2). To this end, we isolated Treg cells from
the following populations from healthy human blood: the fraction
(Fr.) II population (CD45RA and CD25hi) expressing the highest
amounts of Foxp3, activation, and suppressive capacity (Miyara
et al., 2009), theFr. I population (CD45RA+CD25intFoxp3lo),which
are suppressiveandcanconvert to eTregcells, and theFr. III pop-
ulation (CD45RACD25intFoxp3lo) which have been reported to
produce IL-17 while retaining their suppressive ability (Afzali
et al., 2013). All of these Treg cell subsets express the integrin
av subunit (Figure S5B). However, comparable to our data in
mice showing highest expression of integrin b8 mRNA on acti-
vated/eTreg cells, we found that the human Fr. II effector Treg
cell population expresses the highest amounts of integrin b8 (Fig-
ure 7B). The intermediately suppressive Fr. III Treg cell population
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Figure 6. Lack of Integrin b8 Expression by
Foxp3+ Treg Cells Does Not Alter Treg Cell
Maintenance or Stability during Inflammation,
but Reduces TGF-b Signaling in Transferred T
Cell Populations
(A) Analysis of integrin b8-sufficient or KO Treg cell
populations in ‘‘natural chimera’’ female mice,
heterozygous for foxp3YFP-Cre and either Itgb8WT/WT
or Itgb8fl/fl. Representative flow cytometry plots of
Foxp3+YFP-Cre and Foxp3+YFP-Cre+ Treg cells
from mLN and mean percent population data from
spleen, mLN, and LILP. Error bars represent SEM.
Data (n = 3–6) are from three independent experi-
ments.
(B–I) Rag2/ mice received 0.5 3 106 CD45.1+
CD45RBhi T cells, followed 2 weeks later by 0.253 106
control (Itgb8fl/flCre) or Itgb8 KO (Itgb8fl/flCd4-Cre+)
Treg cells (CD4+CD45.1CD45RBloCD25hi). Large in-
testinal T cell and Treg cell populations were examined
6 weeks later.
(B) Representative flow cytometry plots showing
Foxp3 expression of transferred naive congenic
CD45.1+ T cells, CD45.1 control, or Itgb8 KO Treg
cells and gating strategy after analysis of transferred
Treg cell (blue), pTreg cell arising from transferred
naive T cells (purple), and transferred CD4+ T cell (red)
populations.
(C) Percentage of different Treg cell subsets present
(transferred Treg cells and pTreg cells induced from
transferred T cells in total T cell population).
(D and E) Percentage Foxp3 expression (D) and
Foxp3 expression levels (E) in transferred Treg cell
populations.
(F) Representative flow cytometry plots of intracellular
IFN-g and IL-17 expression in transferred Treg cell
populations (blue).
(G) Mean percentage expression of IFN-g and IL-17 in
transferred Treg cell population.
(H and I) Representative histograms (H) and mean MFI
data (I) of pSmad2/3 expression in transferred naive
CD45.1+CD4+ T cells and transferred CD45.1Foxp3+
Treg cells. Data (n = 9–10) are from three independent
experiments.
See also Figure S4 and Tables S1 and S2.
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Figure 7. Human Effector Treg Cells Express Integrin b8
(A) RNA was isolated from human peripheral blood naive T cells (CD4+
CD127+CD45RA+CD25), effector/memory (CD4+CD127+CD45RACD25),
and Treg cells (CD4+CD127CD25+) and integrin b8 expression measured by
qPCR. b8 mRNA were normalized to the housekeeping gene B2M and pre-
sented relative to naive T cell levels (naive, n = 8; effector/memory, n = 7; Treg
cell, n = 4).
(B) Fr. I CD45RA+CD25++ (Foxp3int) ‘‘resting,’’ Fr. II CD45RACD25+++ (Fox-
p3hi) ‘‘activated,’’ and Fr. III CD45RACD252+ (Foxp3int) Treg cell subsets were
sorted and integrin b8 expression measured (Fr. I, n = 3; Fr. II, n = 4; Fr. III,
n = 4).
Error bars represent SEM. See also Figure S5.
912 Immunity 42, 903–915, May 19, 2015 ª2015 The Authorsalso expresses integrin b8, albeit at lower levels than the more
suppressive Fr. II population, whereas the resting Fr. I Treg cell
population does not express detectable levels of integrin b8 (Fig-
ure 7B). Taken together, thesedata suggest that, similar to obser-
vations in mice, human eTreg cell populations express integrin
avb8 and this expression directly correlates with their ability to
suppress T cell responses (Miyara et al., 2009).
DISCUSSION
Despite strong evidence indicating that TGF-b plays a non-
redundant role in Treg-cell-mediated suppression of T cells
in vivo, the mechanisms by which TGF-b is regulated during
Treg-cell-mediated suppression are completely unknown. We
nowdemonstrate that Treg cells are specialized to activate latent
TGF-b due to expression of the TGF-b-activating integrin avb8,
with activated/eTreg cells showing highly upregulated expres-
sion of the integrin in both mice and humans. Although expres-
sion of integrin avb8 on Treg cells is not required to maintain
T cell tolerance or prevent T-cell-mediated inflammation, it is
essential to suppress T cell responses during ongoing inflamma-
tion. These results therefore identify a novel mechanism by
which activated Treg cells specifically control inflammatory
T cells, highlighting a key role for Treg-cell-mediated activation
of latent TGF-b in suppression of harmful T cell responses.
Exactly how integrin avb8 mediates activation of TGF-b by
Treg cells is not clear. Integrin avb8 binds to an RGD motif pre-
sent in LAP, and activation of TGF-b by integrin avb8 has been
proposed to involve the membrane metalloprotease MMP14 in
airway cells (Mu et al., 2002), which cleaves LAP to release active
TGF-b. However, we find no evidence for increased expression
of MMP14 in either naive Treg cells or eTreg cell subsets
compared to naive T cells (data not shown), and therefore the
role for MMP14 in promoting enhanced integrin avb8-mediated
TGF-b activation in Treg cells is unclear. Additionally, whether in-
tegrin avb8 expression in a T cell is sufficient to convey a regula-
tory phenotype is unknown, although it is likely that additional
factors synergize with the integrin b8-TGF-b pathway to mediate
Treg cell suppression during inflammation.
Lack of integrin avb8 expression on Treg cells completely
abrogated their ability to suppress T cell responses during
inflammation, so it was important to determine the mechanism
by which Treg cell expression of integrin avb8 controlled inflam-
matory T cells. Treg cells can convert naive T cells into pTreg
cells (Andersson et al., 2008; Edwards et al., 2013). Therefore,
one possibility for the failure of Itgb8 KO Treg cells to suppress
inflammation was a failure to convert colitic T cells into pTreg
cells, thus lacking so-called ‘‘infectious tolerance.’’ Similarly,
lack of integrin avb8-mediated TGF-b activation could lead to
reduced stability of Treg cells, given that TGF-b plays an impor-
tant role in maintenance of Foxp3 expression (Marie et al., 2005)
and the ability of Treg cells that lose Foxp3 expression to
become pro-inflammatory ‘‘ex-Treg cells’’ during inflammation
(Komatsu et al., 2014; Zhou et al., 2009). However, we observed
equivalent percentages of pTreg cells induced in the transferred
T cell population in colitis models, and also equivalent percent-
ages of transferred control and Itgb8 KO Treg cells expressing
similar levels of Foxp3, strongly indicating that induction of pTreg
cells and stability of transferred Treg cells is not dependent on
expression of integrin avb8. These findings fit with previous ob-
servations in vitro, which suggest that infectious tolerance is in-
dependent of the actions of av integrins (Andersson et al., 2008).
Additionally, transfer of Itgb8 KO Treg cells to Rag2/ mice
alone did not result in inflammation, and expression of key addi-
tional suppressivemarkers of Foxp3+ Treg cells appeared equiv-
alent between control and Itgb8 KO Treg cells, indicating that
lack of integrin avb8 expression by Treg cells does not result in
conversion of these cells to a pathogenic phenotype. Instead,
we observed that, whereas transfer of control Treg cells into
mice receiving naive T cells 2 weeks earlier resulted in induction
of TGF-b signaling (phosphorylation of Smad2/3) in colitic T cells,
such induction was severely diminished when Treg cells lacked
expression of integrin avb8. One potential caveat to this obser-
vation is that inflammation present when Itgb8 KO Treg cells
do not rescue colitis might affect pSmad2/3 signaling. However,
we also show that T cells sense less TGF-b in the presence of
Itgb8KO versus control Treg cells in settings early after co-trans-
fer of T cells and Treg cells, when no inflammation is present.
We also observed a significant decrease in TGF-b signaling in
Treg cells lacking integrin avb8, suggesting that Treg cell activa-
tion of latent TGF-b can act in an autocrine fashion during inflam-
mation, in addition to acting in a paracrine manner to suppress
CD4+ T cells. However, Treg cells incapable of responding to
TGF-b signaling via the expression of a dominant-negative
TGF-b receptor type II (Fahle´n et al., 2005), depletion of TGF-b
receptor II (Sledzinska et al., 2013), or deficiency in the down-
stream TGF-b signaling molecule Smad3 (Kullberg et al., 2005)
are still able to suppress T-cell-mediated colitis, in contrast to
the inability of T cells that cannot sense TGF-b to be suppressed
by Treg cells (Fahle´n et al., 2005). Thus, taken together with
previous studies, our data support a model in which TGF-b,
activated by integrin avb8 expressed by Treg cells, acts in a
paracrine fashion upon CD4+ T cells to suppress inflammation.
An important outstanding question is which cells produce the
functionally important TGF-b that is activated by Treg-cell-
expressed integrin avb8? Controversy still exists as to whether
TGF-b production by Treg cells is essential for their suppressive
function, with different groups showing that Treg cells unable to
produce TGF-b either are capable (Fahle´n et al., 2005; Kullberg
et al., 2005) or incapable (Li et al., 2007; Nakamura et al., 2004)
of suppressing T cells in transfer colitis models. Importantly, how-
ever, in amodel of colitiswhere itwas found that TGF-b1-deficient
Treg cells were capable of suppressing inflammation to the same
extent as control Treg cells, use of a TGF-b blocking antibody
completely abrogated Treg-cell-mediated suppression, showing
that TGF-b from non-Treg cell sources is capable of promoting
suppression of inflammatory T cells (Fahle´n et al., 2005). T cells
that cannot express TGF-b1 can still be suppressed by Treg cells
in colitis models, suggesting that T-cell-derived TGF-b is redun-
dant for Treg cell function (Li et al., 2007). However, when both
T cells and Treg cells cannot make TGF-b, Treg cells show poor
suppressive function (Li et al., 2007). Thus, these data suggest
that a combination of T-cell- and Treg-cell-produced TGF-b are
important in mediating suppression by Treg cells. Given that
many different hematopoietic and non-hematopoietic cells pro-
duce latent TGF-b and that high levels of latent TGF-b are found
throughout the body, we propose that there will be some redun-
dancy in the cell typeproducing functionally important latent com-plex for Treg-cell-mediatedsuppression.However, our data show
that integrin avb8-mediated activation of latent TGF-b by Treg
cells is absolutely required for the Treg-cell-mediated suppres-
sion of inflammatory T cell responses.
Another key observation from our study is that, although
expression of integrin avb8 by Treg cells is essential for Treg-
cell-mediated suppression of T cells during ongoing inflamma-
tion, this pathway is not essential for Treg-cell-mediated suppres-
sionof self-harmful T cells duringhomeostasis.Mutations in foxp3
that result in lack of Treg cells result in lethal autoimmune disease
in both mice and humans. However, lack of integrin avb8 specif-
ically on Treg cells does not result in any overt inflammatory
phenotype, strongly indicating that alternative mechanisms
contribute to Treg-cell-mediated control of T cell homeostasis.
Suchmechanisms probably include IL-10-mediated suppression
of T cells, given that lack of IL-10 production by Foxp3+ Treg cells
in mice results in spontaneous inflammation at mucosal surfaces
(Rubtsov et al., 2008). Additionally, in agreementwith recent work
(Edwards et al., 2014), Treg-cell-expressed integrin avb8 appears
dispensable for inhibition of the initial development of inflamma-
tion in models of colitis (when T cells and Treg cells are co-trans-
ferred into Rag2/ mice), again suggesting that alternative
pathways are important in keeping T cells in check at rest. Inter-
estingly, integrin b8-deficient Treg cells co-transferred with naive
T cells into Rag2/ mice still suppress colitis, despite an initial
reduction in TGF-b signaling in transferred T cells and an initial
reducedability tocontrol T cell expansion.However, 6weeksafter
co-transfer, CD4+ T cells show identical heightened pSmad2/3
levels in the presence of integrin b8 KO Treg cells and control
Treg cells. Thus, together with data showing that T cells that are
refractive to TGF-b signaling cannot be suppressed by Treg cells
(Fahle´n et al., 2005), these results suggest that, when Itgb8 KO
Treg cells are co-transferred with T cells, there is an alternative
source of active TGF-b later after transfer that contributes to
TGF-b-mediated suppression of colitic T cells.
We have discovered that integrin avb8 expression is upregu-
lated on activated/eTreg cells, specifically on a KLRG1+ subset
that have been shown to represent a terminally differentiated sub-
set of eTreg cells (Feuerer et al., 2010). This finding fits well with a
specific role for Treg-cell-expressed integrin avb8 in suppressing
T cells during active inflammation, when T cell and Treg cell acti-
vationwill be prevalent. Indeed, we find that the KLRG1+ Treg cell
subset is significantly expanded during inflammation. Our work
therefore highlights the importance of understanding context-
specific pathways by which Treg cells promote suppression in
order to better therapeutically target these cells; for example, to
promote immune suppression during active disease.
Finally, akin to observations in mice, we find that human Treg
cells are specialized to express high levels of integrin avb8 and
that this expression is enriched on the eTreg cell population.
Thus, it appears that the expression profile of integrin avb8 trans-
lates directly from mouse studies, indicating that this pathway
might be a useful therapeutic target in manipulation of human
Treg cell suppressive function. Adoptive transfer of human
Treg cells is currently in clinical trials for suppression of inflam-
mation in type I diabetes and transplantation (Tang and Blue-
stone, 2013), so identification of pathways that can be targeted
to upregulate the suppressive capacity of these cells are likely
to be extremely beneficial.Immunity 42, 903–915, May 19, 2015 ª2015 The Authors 913
In conclusion, we have identified that both mouse and human
Foxp3+ Treg cells express high levels of the integrin avb8, which
is directly responsible for their ability to activate latent TGF-b,
and lack of this pathway results in a failure of Treg cells to
suppress T-cell-mediated inflammation. These data not only
highlight a novel mechanism by which Treg cells mediate sup-
pression via TGF-b, but also highlight potential specific treat-
ments, via the manipulation of integrin avb8, to modulate Treg
cell function to promote suppression of inflammation.
EXPERIMENTAL PROCEDURES
Animals
Mice lacking T-cell- or Treg-cell-specific expression of integrin b8 were pro-
duced via crossing a conditional floxed allele of b8 integrin with Cd4-Cre
(Travis et al., 2007) or foxp3YFP-Cre (Rubtsov et al., 2008; gift fromDr. A. Ruden-
sky, Memorial Sloan-Kettering Cancer Center, New York) mice. Rag2/ and
foxp3GFP mice were gifts from Dr. K. Okkenhaug (Babraham Institute, Cam-
bridge) and Dr. A. Rudensky, respectively. Mice were maintained in SPF
conditions at the University of Manchester and in AniCan, Center Le´on Be´rard,
Lyon, and used at 6 to 12weeks of age. Stated n numbers are cumulative num-
ber of mice used throughout experiments.
Treg Cell Activation
Treg cells were incubated overnight in 1 mg/ml of anti-CD3 and anti-CD28 anti-
body, and 5 ng/ml rhIL-2 or as described previously (Edwards et al., 2013).
TGF-b Activation Assay
T cell subsets were incubated overnight with a TGF-b reporter cell line (Abe
et al., 1994) and luciferase activity detected via the Luciferase Assay System
(Promega). TGF-b activity was determined as previously described (Worthing-
ton et al., 2011b).
T Cell Transfer Colitis
Naive CD3+CD4+CD45RBhiCD25 T cells were isolated from congenic
CD45.1+ or WT mice and 0.53 106 were injected i.p. into Rag2/mice alone,
with 0.253 106WT or Itgb8KOTreg cells (CD3+CD4+CD45RBloCD25hi), or fol-
lowed 2 or 4 weeks later by 0.25 3 106 WT or Itgb8 KO Treg cells or a 50/50
mix. Miceweremonitored weekly for wasting disease. At 6–8weeks after initial
T cell transfer, 53 106 LILP cells were stimulated with anti-CD3 and anti-CD28
antibody (1 mg/ml) and supernatants were examined via ELISA or stimulated
overnight with cell stimulation cocktail (eBioscience) and examined for cell
populations and intracellular cytokines via flow cytometry.
Histological Assessment of Inflammation
Tissues were fixed in 4% neutral buffered formalin and lungs were perfused
before 5 mm paraffin-embedded sections were cut and stained with hematox-
ylin and eosin. Colitic inflammation was scored in a blinded fashion using a 0–3
scoring system based on the following five criteria: colon length, crypt hyper-
plasia and goblet cell depletion, lamina propria leukocyte infiltration, area
affected, and severe break down of tissue architecture.
DSS Colitis Model
Mice received 1% DSS in drinking water and were monitored daily for weight
loss before sacrifice at day 9 after treatment, before tissue samples were taken
for histology and LILP cells were isolated (see Supplemental Experimental Pro-
cedures) and stained via flow cytometry.
DTH Model
Mice were immunized by s.c. injection of 300 mgOva (Grade VI, Sigma-Aldrich)
in 200 ml PBS/CFA emulsion (Sigma-Aldrich) and challenged 2 weeks later by
s.c. injection of 50 mg Ova in 20 ml PBS into the right ear pinna while 20 ml PBS
alone was injected into the left. Ear thickness was measured in a blinded
fashion prior to and 48 hr after challenge with a caliper micrometer. Ears
were split and digested dermis side down in 0.8% Trypsin at 37C for
30 min before digestion to single-cell suspension in 0.5 Wunch units/ml Liber-914 Immunity 42, 903–915, May 19, 2015 ª2015 The Authorsase TM (Roche) at 37C for 1 hr. Ear draining lymph nodes were isolated, and
single-cell suspensions were re-stimulated and examined via flow cytometry
as previously described.
Statistical Analysis
Results are expressed as mean ± SEM. Where statistics are quoted, two
experimental groups were compared via the Student’s t test for non-para-
metric data. Three or more groups were compared with ANOVA, with Tuckey’s
post-test. p < 0.05was considered statistically significant; *p < 0.05, **p < 0.01,
***p < 0.005.
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